Table 3.
Neurometabolite predictors of heavy drinking days+ and percentage days abstinent+ throughout the trial by linear regression analysis, and weighted effects with recent alcohol consumption (24 h).
| Heavy drinking days | R2 | F | B | p |
|---|---|---|---|---|
| Model 1 | 0.24 | 2.61 | 0.10 | |
| GSH/Cr | −0.37 | 0.18 | ||
| NAA/Cr | −0.17 | 0.53 | ||
| Model 2**, weighted by recent alcohol consumption, R2 change = 0.61 |
0.85 | 14.28 | 0.01 | |
| GSH/Cr* | −1.22 | 0.01 | ||
| NAA/Cr | 0.41 | 0.23 | ||
| Percentage days abstinent | ||||
| Model 1 | 0.10 | 0.49 | 0.62 | |
| GSH/Cr | 0.06 | 0.83 | ||
| NAA/Cr | 0.19 | 0.52 | ||
| Model 2*, weighted by recent alcohol consumption, R2 change = 0.62 |
0.72 | 6.50 | 0.04 | |
| GSH/Cr | 0.99 | 0.06 | ||
| NAA/Cr | −0.18 | 0.68 | ||
+ Calculated from the time of scanning (on average 17 days) to the end of treatment (week 12).
*
Significant at p < 0.05,
**
Significant at p < 0.01, independent of treatment status. For both treatment outcomes, when considering just the patients that consumed alcohol within the last 24 h, the model yielded the highest R2 whereby GSH was a significant and a trend for significant predictor for heavy drinking days and percentage days abstinent, respectively.